Clinical Trial Update: Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating image-guided hypofractionated radiation therapy with nelfinavir mesylate and PD-1/PD-L1 inhibitors in advanced melanoma, lung, or ki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Kidney Carcinoma
• Lung Non-small Cell Cancer
• Lung Non-small Cell Lung Cancer
• Renal Cell Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Nelfinavir mesylate (nelfinavir)
• Pembrolizumab (pembrolizumab)
• nivolumab (nivolumab)

Snippet

Sponsor: University of Washington | Conditions: Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-06-22